In order to broaden its portfolio for Crohn’s disease, Takeda has agreed to acquire the ex-US rights to Cx601 from the Belgian company,TiGenix. The asset is currently undergoing review by the European Medicines Agency (EMA) and the deal could be worth up to EUR390 M (US$434.38 M), including EUR25 M (US$27.84 M) upfront.